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Volume xAvailable online XXXNext-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a short time frame at an
affordable cost. While this technology has been widely implemented, there are no recommendations from scientific
societies about its use in oncology practice. The European Society for Medical Oncology (ESMO) is proposing three
levels of recommendations for the use of NGS. Based on the current evidence, ESMO recommends routine use of
NGS on tumour samples in advanced non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian
cancers and cholangiocarcinoma. In these tumours, large multigene panels could be used if they add acceptable
extra cost compared with small panels. In colon cancers, NGS could be an alternative to PCR. In addition, based on
the KN158 trial and considering that patients with endometrial and small-cell lung cancers should have broad
access to anti-programmed cell death 1 (anti-PD1) antibodies, it is recommended to test tumour mutational burden
(TMB) in cervical cancers, well- and moderately-differentiated neuroendocrine tumours, salivary cancers, thyroid
cancers and vulvar cancers, as TMB-high predicted response to pembrolizumab in these cancers.
Outside the indications of multigene panels, and considering that the use of large panels of genes could lead to few
clinically meaningful responders, ESMO acknowledges that a patient and a doctor could decide together to order a
large panel of genes, pending no extra cost for the public health care system and if the patient is informed about
the low likelihood of benefit. ESMO recommends that the use of off-label drugs matched to genomics is done only
if an access programme and a procedure of decision has been developed at the national or regional level. Finally,
ESMO recommends that clinical research centres develop multigene sequencing as a tool to screen patients eligible
for clinical trials and to accelerate drug development, and prospectively capture the data that could further inform
how to optimise the use of this technology.
Key words: next-generation sequencing (NGS), genomic alterations, metastatic cancersondence to: Prof. Fabrice André, ESMO Head Office e Scientific and
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xx - Issue xxx - 2020INTRODUCTION
Next-generation sequencing (NGS) allows sequencing of a
high number of nucleotides in a short time frame and at
an affordable cost per patient.1e3 In this document, we
will discuss the clinical utility of using NGS as ahttps://doi.org/10.1016/j.annonc.2020.07.014 1
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Figure 1. Method to develop recommendation about NGS in daily practice.
ESCAT, ESMO Scale for Clinical Actionability of molecular Targets.
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(small versus large panels) in frequent diseases. The rec-
ommendations will be done at three levels: from a public
health perspective, from the perspective of academic
clinical research centres and the level of each individual
patient. NGS has recently moved into the clinics with the
aim of sequencing long and complex genes and/or mul-
tiple genes per tumour sample, in order to identify driver
and/or targetable alterations. Pioneering studies have
shown that NGS presents a good analytical validity to
detect clonally dominant alterations.4 Based on this
observation, several companies and academic centres
have implemented NGS assays to guide treatment de-
cisions. While this technology has been widely imple-
mented, there are no recommendations from scientific
societies about their use in daily clinical practice. Several
prospective trials have reported outcomes associated
with the use of multigene sequencing. In the SHIVA trial,
the use of multigene sequencing did not improve
outcome in patients with metastatic hard-to-treat cancers
in comparison with unmatched therapies.5 In the single-
arm MOSCATO trial, the use of multigene sequencing
and comparative genomic hybridisation (CGH) arrays was
associated with an improved progression-free survival
(PFS) in 30% of patients and an objective response rate
(ORR) of 11%.6 Several other studies have consistently
reported that ORRs ranged between 10% and 30% in
patients whose tumours harboured actionable alter-
ations.7e10 One of the major issues with most of the
prospective trials testing multigene sequencing is the
exclusion of patients whose tumours present a genomic
alteration that matches an approved drug. Aside from
large prospective trials, several cases have been reported
to present an outlier sensitivity to a drug given based on
an unforeseen, non-recurrent, somatic genomic alter-
ation.11,12 In the present article, we present the European
Society for Medical Oncology (ESMO) recommendations
about whether and how tumour multigene NGS could be
used to profile metastatic cancers.METHOD
The ESMO Precision Medicine Working Group has set up a
group of experts in the field of clinical cancer genomics in
order to address the following questions:
Should NGS be used in daily practice?
If so, should large panels of genes be used?
These questions should be addressed from the perspec-
tive of public health, academic clinical research centres and
from the perspective of the individual patients.
In order to address these questions, the group devel-
oped the method summarised in Figure 1. The general
strategy was to determine whether NGS can substitute
complex or multiple testings. First, all recurrent genomic
alterations were identified in the eight cancers that are
associated with highest number of deaths in the world.13
The ESMO Scale for Clinical Actionability of molecular
Targets (ESCAT) ranking was then determined for each2 https://doi.org/10.1016/j.annonc.2020.07.014alteration. ESCAT is a framework that ranks a match be-
tween drug and genomic alterations, according to their
actionability.14 ESCAT level I means that the match of an
alteration and a drug has been validated in clinical trials,
and should drive treatment decision in daily practice.
ESCAT level II means that a drug that matches the
alteration has been associated with responses in phase I/
II or in retrospective analyses of randomised trials. ESCAT
level III includes alterations that are validated in another
cancer, but not in the disease-to-treat. ESCAT level IV
includes hypothetically targetable alterations based on
preclinical data. ESCAT ranking was generated for each
alteration by medical oncologists with an expertise in
genomics, then validated by two external experts and by
the Working Group. From the ESCAT ranking and preva-
lence of alterations for each tumour type, we calculated
the number of patients to test with NGS, to identify one
patient that can be matched to an effective drug in daily
practice (ESCAT level I). The main document reports these
numbers with the hypothesis that NGS has a perfect
analytical validity, while Supplementary Tables, available
at https://doi.org/10.1016/j.annonc.2020.07.014, report
these numbers taking a hypothesis of 99% and 95%
sensitivity/specificity.15 We assume that there is no
proven impact in terms of public health of detecting level
IIeIV actionable alterations. Finally, in addition to ESCAT
ranking, the group integrated the results of the KN158
study16 in the recommendations. The KN158 study eval-
uated the efficacy of pembrolizumab single agent ac-
cording to tumour mutational burden (TMB) in 10
different diseases.Volume xxx - Issue xxx - 2020
Table 1. Recommendations and guidelines for the standardisation of
multigene sequencing
Society guidelines Author/journal
Joint Recommendation of the
Association for Molecular Pathology
and the College of American
Pathologists
Roy S, et al. J Mol Diagn. 2018.136
Canadian College of Medical
Geneticists
Hume S, et al. J Med Genet.
2019.137
College of American Pathologists www.cap.org 2020.138
Szymanski J, et al. J Pathol
Inform. 2018.139
Burke W, et al. Curr Protoc Hum
Genet. 2014.140
US FDA Kaul K, et al. J Mol Diag. 2001.141
IQN Path Deans Z, et al. Virchows Arch.
2017.142
Matthijs G, et al. Eur J Hum
Genet. 2015.143
A Joint Consensus Recommendation of
the Association for Molecular Pathology
and College of American Pathologists
Jennings L, et al. J Mol Diagn.
2017.144
College of American Pathologists Aziz N, et al. Arch Pathol Lab
Med. 2015.145
FDA, Food and Drug Administration; IQN Path, International Quality Network for
Pathology.
F. Mosele et al. Annals of OncologyMULTIGENE SEQUENCING: PREREQUISITES FROM THE
TECHNICAL SIDE
In vitro diagnostic tests, such as NGS assays, can be broadly
separated into two main categories. On one hand, there are
manufactured products (reagents, instruments, kits) which
have been cleared or approved by the respective authorities
[e.g. US Food and Drug Administration (FDA)] and are sold
to clinical laboratories for subsequent use. There are
numerous instances where there are unmet analytical or
clinical needs, not uncommonly due to the lack of approved
and commercially available assays; in these cases,
laboratory-developed tests (LDTs) are being designed by
and deployed for clinical decision-making within a single
clinical, often academic, laboratory. In the dynamic and fast-
moving field of cancer precision medicine and molecular
pathology, LDTs play a central role as they are often driving
diagnostic innovation at times when no approved options
exist. Regardless of the in vitro diagnostic category that is
being used in a clinical laboratory, an environment that
continuously assures and monitors assay quality and per-
formance is critical, as inadequate validation and use of
assays could place patients at risk. Whilst the assessment
of test characteristics and quality assurance schemes are
governed by country-specific legislation and different reg-
ulatory models, technical parameters, including modality of
sequencing, sequencing depth, fraction of on-target reads,
alignment quality, read quality, error rates, types of sources
of DNA [ctDNA, frozen, formalin-fixed paraffin-embedded
(FFPE)], minimal tumour cell content are essential and
combined under the umbrella of ‘analytical validity’. Once
the analytical validity and the robustness of the assay are
ascertained, its clinical validity and clinical utility need to be
considered. Professional groups have endeavoured to pro-
vide guidelines for the standardisation of the parameters of
sequencing, data analysis and interpretation of the findings,
and are listed in Table 1.
In fact, a framework that includes standardised validation
protocols and reflects the concepts of (i) analytical validity
(i.e. the ability of a test to accurately measure the analyte of
interest as e.g. defined by the parameters: accuracy, pre-
cision, sensitivity, specificity, positive and negative predic-
tive values), (ii) clinical validity (i.e. the accuracy with which
a genetic test identifies a particular clinical condition with
respect to a diagnostic, prognostic or predictive category)
and (iii) clinical utility (i.e. whether the test and any sub-
sequent interventions result in an improved health
outcome among people with a positive test result and the
risks that occur as a result of the test being carried out)
should be universally considered and applied. ESMO rec-
ommends that genomic reports include the ranking of the
genomic alterations either by ESCAT or OncoKb.17RECOMMENDATIONS
General frame
Recommendations for NGS (summarised in Table 2) are
done at three levels.Volume xxx - Issue xxx - 20201. Recommendations for daily practice (ESCAT level I) aim
to reflect the impact of the use of tumour multigene
NGS on public health.
2. Recommendations for clinical research centres aim to
determine whether performing multigene sequencing
could increase access to innovation, accelerate drug
development and could therefore be a mission of clin-
ical research centres.
3. Patient-centric recommendations.Health economics evidence
From a payer perspective, evidence of the cost-effectiveness
of the use of multigene sequencing in daily practice is
weak.18e21 We identified two economic studies in non-small-
cell lung cancer (NSCLC). The first one has compared the per-
formance of targeted NGS panels with traditional assays in an
EGFR-mutant predominant population.22 The second one has
studied the cost-effectiveness of multigene panel sequencing
compared with single-marker testing.23 These studies suggest
that multigene sequencing in NSCLC is moderately cost-
effective. Moreover, implementation of multigene
sequencing in daily practice requires investments that have to
be considered, especially regarding sequencing and bioinfor-
matics workflows in order to deliver results to clinicians in a
timely manner.24 Finally, from a public health perspective, it
must also be considered that the results of NGS panels could
lead to recommend expensive drugs outside of their
approved indications.25 There is a need to regulate the vol-
umes of NGS procedures at the national level.GENOMIC ALTERATIONS IN ADVANCED NON-SQUAMOUS
NSCLC CLASSIFIED ACCORDING TO ESCAT
EGFR mutations represent the first driver alterations iden-
tified in advanced non-squamous NSCLC.26 Most of themhttps://doi.org/10.1016/j.annonc.2020.07.014 3
Table 2. Summary recommendations
Tumour types General recommendations for daily practice Recommendation for clinical research
centres
Special considerations for patients
Lung adenocarcinoma Tumour multigene NGS to assess level I
alterations. Larger panels can be used only on
the basis of specific agreements with payers
taking into account the overall cost of the
strategy (drug includeda) and if they report
accurate ranking of alterations. NGS can either
be done on RNA or DNA, if it includes level I
fusions in the panel.
It is highly recommended that clinical
research centres perform multigene
sequencing in the context of molecular
screening programmes in order to increase
access to innovative drugs and to speed up
clinical research. This is particularly relevant
in breast, pancreatic and hepatocellular
cancers where level IIeIV alterations are
numerous.
Using large panels of genes could lead to
few clinically meaningful responders, not
detected by small panels or standard
testings. In this context and outside the
diseases where large panels of genes are
recommended, ESMO acknowledges that a
patient and a doctor could decide together
to order a large panel of genes, pending no
extra cost for the public health care system,
and if the patient is informed about the low
likelihood of benefit.
Squamous cell lung
cancers
No current indication for tumour multigene
NGS
Breast cancers No current indication for tumour multigene
NGS
Colon cancers Multigene tumour NGS can be an alternative
option to PCR if it does not result in additional
cost.
Prostate cancers Multigene tumour NGS to assess level I
alterations. Larger panels can be used only on
the basis of specific agreements with payers
taking into account the overall cost of the
strategy and if they report accurate ranking of
alterations.
Gastric cancers No current indication for tumour multigene
NGS
Pancreatic cancers No current indication for tumour multigene
NGS
Hepatocellular
carcinoma
No current indication for tumour multigene
NGS
Cholangiocarcinoma Multigene tumour NGS could be recommended
to assess level I alterations. Larger panels can
be used only on the basis of specific
agreements with payers taking into account the
overall cost of the strategy (drug includeda) and
if they report accurate ranking of alterations.
RNA-based NGS can be used.
Others Tumour multigene NGS can be used in ovarian
cancers to determine somatic BRCA1/2
mutations. In this latter case, larger panels can
be used only on the basis of specific
agreements with payers taking into account the
overall cost of the strategy (drug includeda) and
if they report accurate ranking of alterations.
Large panel NGS can be used in carcinoma of
unknown primary.
It is recommended to determine TMB in
cervical cancer, salivary cancer, thyroid cancers,
well-to-moderately differentiated
neuroendocrine tumours, vulvar cancer,
pending drug access (and in TMB-high
endometrial and SCL cancers if anti-PD1
antibody is not available otherwise).
anti-PD1, anti-programmed cell death 1; DRUP, drug rediscovery protocol; ESMO, European Society for Medical Oncology; NGS, next-generation sequencing; SCL, small-cell lung
cancer; TMB, tumour mutational burden.
a ESMO recommends using off-label drugs matched to genomics only if an access programme and a procedure of decision have been developed at the national or regional level,
as illustrated by the DRUP programme.
Annals of Oncology F. Mosele et al.are in-frame activating deletions in exon 19 and point
hotspot activating mutations in exon 21 (L858R), followed
by acquired resistant mutations in exon 20 (T790M). Several
randomised, phase III trials have shown that EGFR tyrosine
kinase inhibitors (TKIs) improve outcome in patients with
EGFR-mutated NSCLC.27e30 Based on these data, these
specific EGFR mutations reach the highest level in ESCAT.
Point mutations or duplications in exons 18e21 (G719X in
exon 18, L861Q in exon 21, S768I in exon 20) are unusual
EGFR mutations. The efficacies of afatinib and osimertinib
were assessed in prospective, non-randomised trials,
reporting a high ORR and improving PFS.31,32 In addition, in4 https://doi.org/10.1016/j.annonc.2020.07.014patients with exon 20 insertions of EGFR, poziotinib (a se-
lective TKI) presented a limited therapeutic efficacy, also
evaluated in prospective studies.33,34 Another predictive
biomarker that reaches a high position in the ESCAT is ALK
fusion. In randomised trials, anaplastic lymphoma kinase
(ALK) inhibitors confirmed an improvement of clinical out-
comes across patients with ALK-rearranged NSCLC.35-39
Some other alterations like MET exon 14 skipping,
BRAFV600E mutations and ROS1 fusions have been identi-
fied.40 A significant ORR and clinical meaningful benefit
have been shown in phase I/II studies in patients with
NSCLC with METex14 mutations treated with MET TKIs suchVolume xxx - Issue xxx - 2020
F. Mosele et al. Annals of Oncologyas crizotinib, capmatinib or tepotinib, with BRAFV600E mu-
tations that received dabrafenib-vemurafenib and with
ROS1 fusions treated with crizotinib, ceritinib or entrecti-
nib.41e47 No randomised trials were developed for these
aberrations. Based on these results, crizotinib obtained the
Breakthrough Designation from the FDA for METex14-
mutated NSCLC, entrectinib for ROS1-positive NSCLC by the
FDA and dabrafenib-vemurafenib was approved for NSCLC
with BRAFV600E mutation by both the FDA and the European
Medicines Agency (EMA). Fusions involving neurotrophic
tyrosine receptor kinase genes (NTRK1-3) occur with a low
prevalence across different cancer types. Tropomyosin re-
ceptor kinase (TRK) inhibitors (larotrectinib, entrectinib)
have demonstrated durable responses in NTRK fusion-
positive tumours including NSCLC,48e50 leading to agnostic
drug approvals by the EMA and FDA. In addition, LOXO-292
showed efficacy in phase I/II studies in patients with RET
fusion-positive NSCLC, receiving the FDA Breakthrough
Designation.51 Several other drivers with therapeutic po-
tential have been identified including MET amplifications,
KRASG12C mutations (AMG510) and ERBB2 mutations and
amplifications.52e57 Although it has been suggested that
TMB-high (10 mut/Mb) could be a potential predictive
biomarker for immune checkpoint inhibitors (ICIs), this data
is not mature enough to drive decisions in NSCLC.58 Finally,Table 3A. List of genomic alterations level I/II/III according to ESCAT in advance
Gene Alteration Prevalence
EGFR Common mutations (Del19, L858R)
Acquired T790M exon 20
Uncommon EGFR mutations (G719X in exon
18, L861Q in exon 21, S768I in exon 20)
Exon 20 insertions
15% (50%e60%
60% of EGFR mu
NSCLC
10%
2%
ALK Fusions (mutations as mechanism of resistance) 5%
MET Mutations ex 14 skipping 3%
Focal amplifications (acquired resistance
on EGFR TKI in EGFR-mutant tumours)
3%
BRAFV600E Mutations 2%
ROS1 Fusions (mutations as mechanism
of resistance)
1%e2%
NTRK Fusions 0.23%e3%
RET Fusions 1%e2%
KRASG12C Mutations 12%
ERBB2 Hotspot mutations
Amplifications
2%e5%
BRCA 1/2 Mutations 1.2%
PIK3CA Hotspot mutations 1.2%e7%
NRG1 Fusions 1.7%
Volume xxx - Issue xxx - 2020some alterations validated in other tumour types can be
found in patients with NSCLC, but no evidence for drug
efficacy has been reported yet (Table 3A).59e63 In Table 3B,
we have described the main molecular variations classified
by ESCAT in advanced squamous NSCLC.
Summary of recommendations. It is recommended that
a tumour (or plasma) sample from a patient with
advanced non-squamous NSCLC is profiled using NGS
technology, in order to detect level I alterations. Consid-
ering the high frequency of fusions, RNA-based NGS, or
DNA-based NGS designed to capture such fusions, are the
preferred options. There is no evidence that panels
detecting genes with a lower level of evidence brings
additional value from a public health perspective. They
could be used only if the report ranks genomic alterations
according to valid ranking systems (e.g. ESCAT, OncoKB)
and on the basis of specific agreements with payers taking
into account the overall cost of the strategy (including off-
label use of drugs) as compared with small panels.
Regarding this latter point, ESMO does not recommend
the use of off-label drugs matched to genomic alterations,
except if an access programme and a procedure of decision
has been developed at the national or regional level, as
illustrated by the drug rediscovery protocol programme.64
It is recommended that hospitals that run drugd non-squamous non-small-cell lung cancer (NSCLC)
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Annals of Oncology F. Mosele et al.development programmes and clinical trials run multigene
sequencing in the context of molecular screening pro-
grammes, since lung cancer presents some level IIeIV
alterations.
GENOMIC ALTERATIONS IN METASTATIC BREAST CANCER
CLASSIFIED ACCORDING TO ESCAT
ERBB2 amplifications are predictive of clinical benefit of
anti-HER2 therapies, which yield an improvement of overall
survival (OS) and PFS,65e69 while neratinib (an irreversible
pan-HER TKI) has been associated with responses in pa-
tients with ERBB2 mutations.55 Phase III studies reported a
significant improvement of PFS with poly ADP ribose
polymerase inhibitors (PARPi) in patients with germline
BRCA1/2-mutated metastatic breast cancer (mBC).70,71 It is
currently estimated that somatic multigene sequencing
cannot substitute germline testing for BRCA1/2 status.
Alpelisib, an a-selective phosphatidylinositol 3-kinase (PI3K)
inhibitor, improves PFS in patients with HRþ/HER2 mBC
that harbours PIK3CA hotspot mutations, and is approved
in this group of patients.72 Drugs targeting rare alterations
found in different solid tumours, like microsatellite
instability-high (MSI-H) and NTRK fusions, obtained ap-
provals across tumour types.50,73 Nevertheless, NTRK
fusions highly correlate with secretory phenotype and MSI-
high tumours are enriched in triple-negative breast cancers
(TNBCs), where anti-PDL1 antibodies are approved. ESR1
mutations occur in around 20% of patients previously
treated with aromatase inhibitors and are associated
with response to selective estrogen receptor degraders.74
Nevertheless, these data are preliminary and cannot be
used in daily practice. Other promising targets in mBC are
phosphatase and tensin homologue (PTEN) loss of function
mutations and/or homozygous deletions (TNBCs) and
AKT1E17K mutations, which in retrospective and prospective
analyses, respectively, showed a clinical benefit and
increased responsiveness to AKT inhibitors. Nevertheless,
no results are available from practice changing trials
yet.75,76 In addition, NF1 mutations were identified as a
mechanism of endocrine resistance, but there is no targeted
therapy available yet in this genomic segment.77 Lastly,
there are some alterations with no major impact in mBC
that are validated in other malignances (Table 4).55,63,78
Summary of recommendations. Considering that so-
matic sequencing cannot fully substitute germline BRCA
testing, that PIK3CA status can be determined by PCR on
the three hotspots and pending that HER2 testing is6 https://doi.org/10.1016/j.annonc.2020.07.014accurately done by immunohistochemistry (IHC) in the
local centre, there is currently no need to perform tumour
multigene NGS for patients with mBC in the context of
daily practice. From the perspective of clinical research
centres, and considering the high number of level II al-
terations, it is important to include mBC patients in mo-
lecular screening programmes and include them in trials
testing targeted therapies matched to genomic alterations
(AKT1E17K, PTEN, ERBB2 mutations, ESR1 and NF1
mutations).
GENOMIC ALTERATIONS IN METASTATIC COLORECTAL
CANCER CLASSIFIED ACCORDING TO ESCAT
Pivotal randomised trials and meta-analysis highlighted that
hotspot RAS mutations (K-RAS and N-RAS) predict resis-
tance to EGFR monoclonal antibodies (mAbs) in the meta-
static setting.79e81 https://doi.org/10.1093/annonc/mdw235.
The addition of encorafenib (a BRAF inhibitor) to cetuximab
was associated with a significant survival benefit in a recent
phase III trial in patients presenting a BRAFV600E mutation.82
Alterations in mismatch repair proteins (MLH1, MSH2,
MSH6 and PMS2) can be identified by IHC and MSI-H
by PCR to detect smaller length DNA fragments. Testing
for MSI-H is of great clinical interest in metastatic colorectal
cancer (mCRC) because it predicts the efficacy of pem-
brolizumab and nivolumab in this setting.83,84 As mentioned
before, TRK inhibitors showed high efficacy in multi-
histology trials in NTRK fusion-positive tumours50,85; and
mCRC with ERBB2 amplifications/overexpression (detected
with FISH or IHC) presented significant responses with dual
HER2 therapy in prospective studies.86,87 In Table 5 we
mention the main driver alterations categorised according
to ESCAT, including those with a lack of clinical data in
mCRC, but with impact in other tumours.76,88e94
Summary of recommendations. Since most level I al-
terations are hotspot mutations in KRAS, NRAS and BRAF,
and considering that MSI status is determined by IHC or
PCR, there is no need to test samples using multigene NGS
in the context of daily practice. Nevertheless, multigene
NGS can be an alternative to PCR tests only if it does not
generate extra cost compared with standard techniques
already implemented in routine. This would allow detec-
tion of ERBB2 amplifications, and, in some panels, detect
MSI status with high accuracy. If large panel NGS is carried
out, it should include detection of NTRK fusions. As for
mBC patients, patients with mCRC can present oncogenic
alterations for which drugs are being developed and it isVolume xxx - Issue xxx - 2020
Table 4. List of genomic alterations level I/II/III according to ESCAT in
metastatic breast cancer (mBC)
Gene Alteration Prevalence ESCAT References
ERBB2 Amplifications 15%e20% IA Slamon D, et al. N Engl J
Med. 200165
Swain S, et al. N Engl J
Med. 201566
Verma S, et al. N Engl J
Med. 201267
Krop I, et al. Lancet
Oncol. 201468
Murthy R, et al. N Engl J
Med. 202069
Hotspot
mutations
4% IIB Hyman D, et al. Nature.
201855
PIK3CA Hotspot
mutations
30%e40% IA André F, et al. N Engl J
Med. 201972
BRCA1/
2
Germline
mutations
4% IA Robson M, et al. N Engl J
Med. 201770
Litton J, et al. N Engl J
Med. 201871
Somatic
mutations
3% IIIA Balasubramaniam S,
et al. Clin Cancer Res.
201763
MSI-H 1% IC Marcus L, et al. Clin
Cancer Res. 201973
NTRK Fusions 1% IC Doebele RC, et al. Lancet
Oncol. 202050
ESR1 Mutations
(mechanism of
resistance)
10% IIA Fribbens C, et al. J Clin
Oncol. 201674
PTEN Mutations 7% IIA Schmid P, et al. J Clin
Oncol. 201875
AKT1E17K Mutations 5% IIB Hyman D, et al. J Clin
Oncol. 201776
NF1 Mutations
(resistance
biomarker)
6% Not
applicable
Pearson A, et al. Clin
Cancer Res. 202077
MDM2 Amplifications w1% IIIA Dembla V, et al.
Oncotarget. 201878
ERBB3 Mutations 2% IIIB Hyman D, et al. Nature.
201855
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets; MSI-H, microsatellite instability-high.
Table 5. List of genomic alterations level I/II/III according to ESCAT in
metastatic colorectal cancer (mCRC)
Gene Alteration Prevalence ESCAT References
KRAS
NRAS
Mutations
(resistance
biomarker)
44%
4%
Not
applicable
Van Cutsem E, et al. J
Clin Oncol. 201579
Douillard J-Y, et al. N
Engl J Med. 201380
Sorich M, et al. Ann
Oncol. 201581
BRAFV600E Mutations 8.5% IA https://doi.org/10.1
093/annonc/mdw235
Kopetz S, et al. N Engl J
Med. 201982
MSI-H 4%e5% IA Overman M, et al.
Lancet Oncol. 201783
Le DT, et al. J Clin Oncol.
202084
NTRK1 Fusions 0.5% IC Demetri G, et al. Ann
Oncol. 201885
Doebele RC, et al.
Lancet Oncol. 202050
ERBB2 Amplifications 2% IIB Meric-Bernstam F, et al.
Lancet Oncol. 201986
Sartore-Bianchi A, et al.
Lancet Oncol. 201687
PIK3CA Hotspot
mutations
17% IIIA Juric D, et al. J Clin
Oncol. 201890
ATM Mutations 5% IIIA Wang C, et al. Transl
Oncol. 201792
De Bono J, et al. N Engl J
Med. 202093
MET Amplifications 1.7% IIIA https://clinicaltrials.
gov/ct2/show/NCT035
9264194
AKT1E17K Mutations 1% IIIA Hyman D, et al. J Clin
Oncol. 201776
TMB-high in
MSS
1% IIIA Fabrizio D, et al. J
Gastrointest Oncol.
201889
RET Fusions 0.3% IIIA Drilon A, et al. J Clin
Oncol. 201891
ALK Fusions 0.2% IIIA Yakirevich E, et al. Clin
Cancer Res 201688
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets; MSI-H, microsatellite instability-high; MSS, microsatellite
stable.
F. Mosele et al. Annals of Oncologytherefore recommended for clinical research centres to
include patients in molecular screening programmes to
propose access to innovative agents in clinical trials.GENOMIC ALTERATIONS IN ADVANCED PROSTATE CANCER
CLASSIFIED ACCORDING TO ESCAT
Metastatic castration-resistant prostate cancer (mCRPC)
presents aberrations in DNA repair genes with a high fre-
quency (20%e30%). PARPi improved outcomes in patients
with different DNA repair gene alterations in a randomised
phase III trial; however, exploratory per-gene analysis sug-
gested that most of the benefit was obtained in patients
with BRCA1/2 somatic mutations.93 This is supported by
multiple phase II trials, where patients with BRCA1/2 al-
terations achieved the higher response rates. Data about
PALB2, RAD50, RAD51 or BRIP1 mutations are promising
but sparse due to the low frequency of these aberra-
tions.93,95 Other genes involved in DNA repair, like MLH1/
MSH2/MSH6 lead to MSI-H when mutated. Therapy with
ICIs demonstrated effectiveness in multi-histology basketVolume xxx - Issue xxx - 2020studies, although in advanced prostate cancer have shown
minimal activity.73,96,97 PTEN alterations are found very
frequently in mCRPC,98 and AKT inhibitors in combination
with abiraterone showed antitumour activity in a retro-
spective analysis of a randomised phase II trial.99 Pre-
liminary results of IPATential 150, a phase III randomised
trial which evaluated ipatasertib (AKT inhibitor) with abir-
aterone and prednisone compared with standard therapy,
showed an improvement of radiographic PFS (co-primary
end point) in patients with PTEN loss and mCRPC, but not in
the overall population.100 Some alterations ranked level I/II
in other diseases are observed in prostate cancer, but are
not yet validated101 (see Table 6).
Summary of recommendations. In countries where
PARPi are accessible for patients with prostate cancer, it is
recommended to perform NGS on tumour samples to
assess the mutational status of, at least, BRCA1/2. Ac-
cording to the preliminary results of the phase III trial with
AKT inhibitors in patients with PTEN alterations, this genehttps://doi.org/10.1016/j.annonc.2020.07.014 7
Table 6. List of genomic alterations level I/II/III according to ESCAT in
advanced prostate cancer
Gene Alteration Prevalence ESCAT References
BRCA1/
2
Somatic
mutations/
deletions
9% IA De Bono J, et al. N Engl J
Med. 202093
MSI-H 1% IC Cortes-Ciriano I, et al. Nat
Commun. 201796
Abida W, et al. J Clin Oncol.
201897
Marcus L, et al. Clin Cancer
Res. 201997
PTEN Deletions/
mutations
40% IIAa Abida W, et al. Proc Natl
Acad Sci. 201998
De Bono J, et al. Clin Cancer
Res. 201999
NCT03072238100
ATM Mutations/
deletions
5% IIA De Bono J, et al. N Engl J
Med. 202093
PALB2 Mutations 1% IIB Mateo J, et al. N Engl J
Med. 201595
De Bono J, et al. N Engl J
Med. 202093
PIK3CA Hotspot
mutations
3% IIIA Crumbaker M, et al.
Cancers. 2017101
AKT1E17K Mutations 1% IIIA Crumbaker M, et al.
Cancers. 2017101
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets; MSI-H, microsatellite instability-high; PTEN, phosphatase and
tensin homologue.
a A press release suggests that AKT inhibitors could work specifically in PTEN-mutant
prostate cancers. PTEN could be upgraded to IA depending on the magnitude of
benefit and peer review assessment of the report.
Table 7. List of genomic alterations level I/II/III according to ESCAT in
metastatic gastric cancer (mGC)
Gene Alteration Prevalence ESCAT References
ERBB2 Amplifications 16% IA The Cancer Genome Atlas
Research Network. Nature.
2014102
Bang Y-J, et al. Lancet. 2010103
Hotspot
mutations
3% IIIA Hyman D, et al. Nature. 201855
MSI-H 8% IC The Cancer Genome Atlas
Research Network. Nature.
2014102
Marcus L, et al. Clin Cancer Res.
201997
NTRK Fusions 2% IC Drilon A, et al. N Engl J Med.
201848
EGFR Amplifications 6% IIB Maron S, et al. Cancer Discov.
2018104
MET Amplifications 3% IIB Lennerz J, et al. J Clin Oncol.
2011105
Mutations 1.3% IIIA Lee J, et al. Oncotarget. 2015107
PIK3CA Hotspot
mutations
7% IIIA Juric D, et al. J Clin Oncol. 201890
FGFR2 Amplifications 4% IIIA Van Cutsem E, et al. Ann Oncol.
2017109
Loriot Y, et al. N Engl J Med.
2019110
ATM Mutations 3% IIIA Bang Y-J, et al. Lancet Oncol.
2017108
BRCA1/
2
Mutations 1%e5% IIIA Balasubramaniam S, et al. Clin
Cancer Res. 201763
ROS1 Fusions <1% IIIA Shaw A, et al. Ann Oncol. 201946
RET Fusions <1% IIIA Oxnard G, et al. J Thorac Oncol.
2018106
ERBB3 Hotspot
mutations
3% IIIB Hyman D, et al. Nature. 201855
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets; MSI-H, microsatellite instability-high.
Annals of Oncology F. Mosele et al.could be added to the panel. Given that they are unlikely
to be cost-effective in these cases, larger panels can be
used only on the basis of specific agreements with payers
taking into account the overall cost of the strategy
(including off-label use of drugs) and pending a ranking
of additional alterations using a valid ranking system.
These panels should include DNA repair genes and MSI
signature.GENOMIC ALTERATIONS IN METASTATIC GASTRIC CANCER
CLASSIFIED ACCORDING TO ESCAT
ERBB2 amplifications are observed in around 15% of gastric
cancers.102 In these patients, trastuzumab demonstrated a
significant improvement of OS in randomised trials.103 Ac-
cording to basket trials, patients with MSI-H and NTRK
fusion-positive tumours treated with ICIs and TRK inhibitors
are expected to provide benefit.48,73 Some limited re-
sponses were observed in patients with EGFR- and MET-
amplified metastatic gastric cancer (mGC) treated with
cetuximab and crizotinib in prospective analysis.104,105
These findings require further investigation. In addition,
many other level I/II aberrations of other cancer types are
observed in gastric cancer, but not validated in this latter
disease.46,55,63,90,106e110 All these alterations are described
in Table 7.
Summary of recommendations. There is no current need
to perform tumour multigene NGS in patients with mGC in
daily practice. Detection of MSI and NTRK fusions should
be done using cheap standard methods.8 https://doi.org/10.1016/j.annonc.2020.07.014GENOMIC ALTERATIONS IN ADVANCED PANCREATIC
DUCTAL ADENOCARCINOMA CLASSIFIED ACCORDING TO
ESCAT
Patients with germline BRCA1/2-mutated advanced
pancreatic ductal adenocarcinoma (PDAC) presented a
longer PFS with maintenance olaparib.111,112 In advanced
PDAC with somatic BRCA1/2 mutations, an increased
response with PARPi has been reported in few patients
included in a prospective trial.113 The panel therefore
considered that somatic BRCA1/2 alterations are not yet
validated in advanced PDAC. As we mentioned for other
tumours, patients with MSI-H and NTRK fusion-positive
tumours presented meaningful clinical benefit with
matched therapies in multi-histology studies.50,97,114,115
Several additional alterations are classified at high level
according to ESCAT in other tumours, but have not yet
shown a significant impact in pancreatic cancer like KRAS,
PIK3CA, BRAFV600E mutations, MDM2, ERBB2 amplifications
and NRG1, ALK, RET, ROS1 fusions.55,91,116e125 The main
drivers of PDAC and their classification are described in
Table 8.
Summary of recommendations. It is not currently rec-
ommended to perform tumour multigene NGS in patients
with advanced PDAC in daily practice. Considering the
unmet medical needs and the high number of alterations
ranked as level IIeIV, ESMO considers it is the mission ofVolume xxx - Issue xxx - 2020
Table 8. List of genomic alterations level I/II/III according to ESCAT in
advanced pancreatic ductal adenocarcinoma (PDAC)
Gene Alteration Prevalence ESCAT References
BRCA1/2 Germline
mutations
1%e4% IA The Cancer Genome Atlas
Research Network. Cancer
Cell. 2017111
Golan T, et al. N Engl J Med.
2019112
Somatic
mutations
3% IIIB Shroff R, et al. JCO Precis
Oncol. 2018113
MSI-H 1%e3% IC Pihlak R, et al. Cancers.
2018115
Marcus L, et al. Clin Cancer
Res. 201997
NTRK Fusions <1% IC Cocco E, et al. Nat Rev Clin
Oncol. 2018114
Doebele RC, et al. Lancet
Oncol. 202050
KRAS Mutations 90% IIIA Zeitouni D, et al. Cancers.
2016116
PIK3CA Hotspot
mutations
3% IIIA Heestand G, et al.
Oncotarget. 2015117
Payne S, et al. J Clin Oncol.
2015118
BRAFV600E Mutations 3% IIIA Hyman D, et al. N Engl J Med.
2015119
MDM2 Amplifications 2% IIIA Azmi A, et al. Eur J Cancer.
2010120
ERBB2 Amplifications/
mutations
1%e2% IIIA Waddell N, et al. Nature.
2015121
Harder J, et al. Br J Cancer.
2012122
Hyman D, et al. Nature.
201855
NRG1 Fusions 1% IIIA Jones M, et al. Clin Cancer
Res. 2019123
ALK Fusions <1% IIIA Singhi A, et al. J Natl Compr
Canc Netw. 2017124
RET Fusions <1% IIIA Drilon A, et al. J Clin Oncol.
201891
ROS1 Fusions <1% IIIA Pishvaian M, et al. J Clin
Oncol. 2018125
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets; MSI-H, microsatellite instability-high.
Table 9. List of genomic alterations level I/II/III according to ESCAT in
advanced hepatocellular carcinoma (HCC)
Gene Alteration Prevalence ESCAT References
NTRK Fusions 1% IC The Cancer Genome Atlas
Research Network. Cancer Cell.
2017111
Drilon A, et al. N Engl J Med.
201848
MSI-H 1% IC Marcus L, et al. Clin Cancer Res.
201997
PIK3CA Hotspot
mutations
4% IIIA André F, et al. N Engl J Med.
201972
MET Amplifications 2%e6% IIIA Rimassa L, et al. Lancet Oncol.
2018127
RAS Mutations 2% IIIA Lim H, et al. Clin Cancer Res.
2018128
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets; MSI-H, microsatellite instability-high.
F. Mosele et al. Annals of Oncologyclinical research centres and their networks to propose
multigene sequencing to patients with advanced PDAC in
the context of molecular screening programmes, in order
for patients to get access to innovative drugs. If multigene
sequencing is not carried out, detection of MSI and NTRK
fusions should be done using cheaper standard methods,
pending drugs are approved and reimbursed.GENOMIC ALTERATIONS IN ADVANCED HEPATOCELLULAR
CARCINOMA CLASSIFIED ACCORDING TO ESCAT
While numerous aberrations are being evaluated, very
few targets currently have impact on clinical de-
cisions.126 As we described for the majority of cancers,
due to their clinical benefit larotrectinib and ICIs were
approved for patients with NTRK fusion-positive and
MSI-H solid tumours, respectively, who have no alter-
native treatments.48,97 There are also other alterations
with strong benefit across different tumour types like
PIK3CA, RAS mutations and MET amplifications,72,127,128
and no clinical evidence in this disease (Table 9).Volume xxx - Issue xxx - 2020Summary of recommendations. It is not currently
recommended to perform tumour multigene NGS in
patients with advanced hepatocellular carcinoma (HCC)
in daily practice. Considering the unmet medical needs
and the number of alterations ranked as level IIeIV,
ESMO considers it is the mission of clinical research
centres to propose multigene sequencing to patients
with advanced HCC in the context of molecular
screening programmes. If multigene sequencing is not
carried out, detection of MSI and NTRK fusions should
be done using cheaper standard methods, pending
drugs are approved and reimbursed.GENOMIC ALTERATIONS IN ADVANCED
CHOLANGIOCARCINOMA CLASSIFIED ACCORDING TO
ESCAT
IDH1 mutations are ranked level I in ESCAT (IA).129 In
addition, pemigatinib, a selective fibroblast growth
factor receptor (FGFR)1,2,3 inhibitor, led to a 35% ORR
in patients with advanced FGFR2 fusion-positive chol-
angiocarcinoma (CC) in a prospective phase II trial,130
getting accelerated approval by the FDA. As we
mentioned previously, patients with MSI-H and NTRK
fusion-positive tumours presented clinically meaningful
benefit with ICIs and TRK inhibitors in basket
studies.50,131 Finally, rapidly accelerated fibrosarcoma/
mitogen-activated protein kinase kinase inhibitors were
associated with 42% OR in patients with advanced CC
and BRAFV600E mutations132 (Table 10). In Table 10 are
also described some alterations with efficacy in other
tumours, but not yet validated in this disease.52,72,93,133
Summary of recommendations. Tumour multigene
NGS could be used to detect level I actionable alter-
ations in cholangiocarcinoma. Given that they are un-
likely to be cost-effective in these cases, larger panels
can be used only on the basis of specific agreements
with payers taking into account the overall cost of the
strategy (including off-label use of drugs) and pending ahttps://doi.org/10.1016/j.annonc.2020.07.014 9
Table 10. List of genomic alterations level I/II/III according to ESCAT in
advanced cholangiocarcinoma (CC)
Gene Alteration Prevalence ESCAT References
IDH1 Mutations 20% IA Abou-Alfa G. K, et al. Ann
Oncol. 2019129
FGFR2 Fusions 15% IB Vogel A, et al. Ann Oncol.
2019130
MSI-H 2% IC Marabelle A, et al. J Clin
Oncol. 2020131
NTRK Fusions 2% IC Doebele RC, et al. Lancet
Oncol. 202050
BRAFV600E Mutations 5% IIB Wainberg Z, et al. J Clin Oncol.
2019132
ERBB2 Amplifications
Mutations
10%
2%
IIIA Javle MM, et al. J Clin Oncol.
2017133
PIK3CA Hotspot
mutations
7% IIIA André F, et al. N Engl J Med.
201972
BRCA 1/2 Mutations 3% IIIA De Bono J, et al. N Engl J Med.
202093
MET Amplifications 2% IIIA Camidge D, et al. J Clin Oncol.
201852
ESCAT, European Society for Medical Oncology (ESMO) Scale for Clinical Actionability
of molecular Targets.
Annals of Oncology F. Mosele et al.ranking of additional alterations using a valid ranking
system.
Other tumour types. While the systematic ranking of
genomic alterations was done exclusively for the eight
more frequent killers, we also assessed the frequency
of level I alterations in other tumour types. In ovarian
cancers, where BRCA1/2 somatic mutations have been
associated with increased benefit to PARPi,134 the use
of multigene NGS is justified. Larger panels can be used
only on the basis of specific agreements with payers
taking into account the overall cost of the strategy
(including off-label use of drugs) and pending an
appropriate method of reporting. While there is no
level I evidence, multigene sequencing could also be
used in carcinoma of unknown primary.135Specific situations
Tumour mutational burden and KN158 study. KN158 has
evaluated the efficacy of pembrolizumab according to TMB
in 10 cancers (anal cancer, cervical cancer, endometrial
cancer, small-cell lung cancer (SCLC), salivary cancer, thyroid
cancers, well-to-moderately differentiated neuroendocrine
tumours (NETs), biliary cancers, vulvar cancer, mesotheli-
oma). Response rates were 27% and 7% in patients with
TMB-high (MSI-low) or TMB-low cancers, respectively. There
was no TMB-high detected in biliary cancers, and the per-
centage of response was lower in TMB-high in anal cancer
and mesothelioma. We can classify TMB as level IIA ac-
cording to ESCAT. If we consider that indications of anti-
PD(L)1 antibodies are broad in endometrial cancers and
SCLC, the TMB should be determined only in cervical can-
cer, NET, salivary cancers, vulvar cancers, thyroid cancers.
Considering that the study was not agnostic, but limited to
few cancers, the group thinks that additional studies are10 https://doi.org/10.1016/j.annonc.2020.07.014needed before implementing TMB in all cancers where
anti-PD(L)1 antibodies are not approved.NTRK fusions. TRK inhibitors have been shown to be
effective in a broad range of cancers. NTRK fusions occur in
<1% of cancers. The incidence of NTRK fusions is very high
in mammary analogue secretory carcinoma of salivary
glands and in secretory breast cancers. A high incidence is
also observed in sarcoma and thyroid cancers. Considering
the very low incidence, the group recommends using NGS
to detect NTRK fusions only in cancers where this tech-
nology is recommended otherwise. In cancers where there
is no need for multigene sequencing, it was considered
that the detection of NTRK fusion is not an argument per
se to recommend NGS since alternative, cheaper, diag-
nostic methods exist. Such alternative, cheaper methods
should be prioritised to screen patients for NTRK fusions, in
countries where TRK inhibitors are available.CONCLUSION
ESMO recommends using tumour multigene NGS in patients
presenting with advanced non-squamous NSCLC, prostate,
ovarian cancers and cholangiocarcinoma. Large panels of
genes can be used if they generate only an acceptable in-
crease in the overall cost, drugs included. In addition, based
on KN158, it is recommended to determine TMB in cervical
cancer, salivary cancer, thyroid cancers, well-to-moderately
differentiated NETs, vulvar cancer, pending drug access. In
colorectal cancers, NGS can be an alternative to PCR-based
tests, if it is not associated with extra cost. ESMO strongly
recommends that clinical research centres perform multi-
gene sequencing as part of their missions to accelerate
cancer research and drug development through clinical tri-
als, provide access to innovation to patients and to collect
data. In addition, economic evaluations alongside clinical
trials should also be implemented to foster evidence in this
field. Outside the indications mentioned before, and
considering that the use of large panels of genes could lead
to identification of few exceptional responders, ESMO ac-
knowledges that a patient and a doctor could decide
together to order a large panel of genes, pending no extra
cost for the public health care system, and if the patient is
informed about the low likelihood of benefit.
These recommendations will need to be updated on a
regular basis as new data emerges for novel therapies
across tumour types.
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